Key Highlights

  • CG Oncology shares climbed roughly 5.75% to $80.68, putting the stock essentially at its 52-week and all-time high, only about 0.4% below the recent peak near $81.01.
  • The rally follows the July 27, 2026 publication of positive Phase 3 BOND-003 trial results for cretostimogene in The Lancet Oncology, plus today's broader biotech-sector rally after Moderna and Merck's melanoma-vaccine trial win.
  • RSI of 65.2 shows a strong up trend that has not yet reached overbought territory, alongside a reiterated Buy rating and $100 price target from H.C. Wainwright.
  • CG Oncology's August 6, 2026 second-quarter update showed roughly $1.0 billion in cash, expected to fund operations through 2029, with a BLA submission targeted for completion in the fourth quarter of 2026.

Bladder-Cancer Trial Data Drives Stock to New Highs

CG Oncology, Inc. (NASDAQ:CGON) rose about 5.75% on August 20, 2026, pushing shares to essentially a fresh 52-week and all-time high near $80.68. The move builds on the July 27, 2026 publication of Phase 3 BOND-003 Cohort C results in The Lancet Oncology, evaluating the company's lead candidate cretostimogene grenadenorepvec for high-risk BCG-unresponsive non-muscle invasive bladder cancer. The trial met its primary endpoint, with 75.5% of patients achieving a complete response and no Grade 3 or higher adverse events reported, reinforcing investor confidence heading into the stock's next regulatory milestones.

Strong Balance Sheet and Approaching BLA Filing

In its second-quarter 2026 results reported August 6, 2026, CG Oncology posted Revenue of $1.2 million and a net loss of $79.1 million, or $0.90 per share, typical for a clinical-stage biotech still pre-commercial. The company held approximately $1.0 billion in cash, which management said should fund operations through 2029. Bladder-preservation data from BOND-003 showed 89% of patients retained their bladders at 12 months and 81% at 24 months. Management also flagged that completion of the Biologics License Application submission is targeted for the fourth quarter of 2026, with Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC anticipated near-term.

Analyst Support Amid Broader Biotech Tailwind

H.C. Wainwright reiterated a Buy rating with a $100 price target on CG Oncology following the BOND-003 publication, citing confidence in the trial data, while Wolfe Research initiated coverage with a more cautious Peerperform rating, anticipating a slower early commercial launch than consensus estimates suggest. Today's added move also coincides with a broader biotech rally tied to Moderna and Merck's positive melanoma-vaccine trial results announced August 19, 2026, which lifted sentiment across clinical-stage oncology and Vaccine names generally. An RSI of 65.2 shows strong momentum without yet flagging as overbought, though the stock remains unprofitable and its valuation reflects substantial expectations for a still-unapproved therapy.

The Takeaway

CG Oncology is trading essentially at its 52-week and all-time high after strong Phase 3 bladder-cancer trial data, a reiterated Buy rating and $100 price target from H.C. Wainwright, and a broader biotech-sector tailwind. These are the verified facts as reported. Whether the stock breaks to a new high may depend on the timing and content of the anticipated Phase 3 PIVOT-006 topline data and progress toward the fourth-quarter 2026 BLA submission.